Viridian Therapeutics, Inc. announced on September 15, 2025, the completion of enrollment in both its REVEAL-1 and REVEAL-2 Phase 3 clinical trials. These trials are evaluating VRDN-003, a subcutaneously delivered, half-life extended, monoclonal antibody, in patients with active and chronic Thyroid Eye Disease (TED), respectively. This milestone indicates significant progress in the development of Viridian's next-generation TED therapy.
VRDN-003 targets the insulin-like growth factor-1 receptor (IGF-1R), the same validated mechanism as veligrotug, but is engineered for convenient at-home self-administration. The completion of enrollment is a crucial step towards generating topline data from these pivotal studies, which are anticipated in the first half of 2026. This data will be essential for supporting a Biologics License Application (BLA) submission for VRDN-003, targeted by the end of 2026.
This operational achievement underscores Viridian's commitment to advancing its pipeline and bringing differentiated treatment options to TED patients. The successful enrollment completion de-risks the clinical timeline for VRDN-003, positioning it as a potential best-in-class subcutaneous therapy that could significantly improve patient convenience and expand the overall TED market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.